158 related articles for article (PubMed ID: 1680592)
1. Molecular genetics of the debrisoquin-sparteine polymorphism.
Gonzalez FJ; Meyer UA
Clin Pharmacol Ther; 1991 Sep; 50(3):233-8. PubMed ID: 1680592
[No Abstract] [Full Text] [Related]
2. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
3. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
4. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM; Skoda RC; Grant D; Blum M
Prog Liver Dis; 1990; 9():307-23. PubMed ID: 2156298
[No Abstract] [Full Text] [Related]
6. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
[TBL] [Abstract][Full Text] [Related]
7. Role of genetic polymorphism in psychopharmacology--an update.
Brøsen K; Sindrup SH; Skjelbo E; Nielsen KK; Gram LF
Psychopharmacol Ser; 1993; 10():199-211. PubMed ID: 8361977
[No Abstract] [Full Text] [Related]
8. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.
Eichelbaum M; Baur MP; Dengler HJ; Osikowska-Evers BO; Tieves G; Zekorn C; Rittner C
Br J Clin Pharmacol; 1987 Apr; 23(4):455-8. PubMed ID: 3472585
[TBL] [Abstract][Full Text] [Related]
9. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
Meyer UA; Skoda RC; Zanger UM
Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
[TBL] [Abstract][Full Text] [Related]
10. Genes encoding drug-metabolizing enzymes: possible role in human disease.
Nebert DW
Basic Life Sci; 1988; 43():45-64. PubMed ID: 2896496
[No Abstract] [Full Text] [Related]
11. Human cytochromes P450: evolution, catalytic activities and interindividual variations in expression.
Gonzalez FJ; Gelboin HV
Prog Clin Biol Res; 1991; 372():11-20. PubMed ID: 1956910
[No Abstract] [Full Text] [Related]
12. CYP2D6 genotype determination in the Danish population.
Brøsen K; Nielsen PN; Brusgaard K; Gram LF; Skjødt K
Eur J Clin Pharmacol; 1994; 47(3):221-5. PubMed ID: 7867674
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
14. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine/sparteine-type polymorphic drug metabolism in wild Clethrionomys rufocanus.
Hoshi H; Masuda M; Yamamoto Y; Suimamoto Y; Kazusaka A; Fujita S
Drug Metab Dispos; 1995 Nov; 23(11):1301-3. PubMed ID: 8591735
[No Abstract] [Full Text] [Related]
16. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
Ho JW; Moody DE
Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Lennard MS
Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
[TBL] [Abstract][Full Text] [Related]
18. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism.
Horai Y; Ishizaki T
Ration Drug Ther; 1988 Jun; 22(6):1-8. PubMed ID: 3051125
[No Abstract] [Full Text] [Related]
20. Comparative pharmacogenetics of sparteine and debrisoquine.
Inaba T; Vinks A; Otton SV; Kalow W
Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
